Treasury-market reprieve could be fleeting with deluge of corporate-bond issuance due in September
“From a bond investors perspective, the bottom line is about where you put your money to work,” says Henry Song, portfolio manager at Diamond Hill…
Five reasons we’re headed for a 10% stock-market correction — or worse
Summer is winding down, and “spooky season” will soon be upon us. That’s just one cause for investor wariness. Source：MarketWatch
Apple’s stock could be the savviest buy within Big Tech, according to this analysis
While other “Magnificent Seven” companies spend big on AI, Apple’s more conservative strategy has turned the stock into a valuable portfolio hedge against…
‘Trump accounts’ won’t help solve Americans’ savings problems. Here’s a better way.
Universal savings accounts are the solution. Source：MarketWatch
9 stocks to ride the industrial sector’s blazing rally
Industrial stocks have gotten expensive, but here are some with the most attractive growth prospects. Source：MarketWatch
I want to be a snowbird, but I’m not sure my $2 million nest egg can sustain two homes
It’s not the purchase price that’s the biggest obstacle, but rather the continuing costs. Source：MarketWatch
Berkshire Hathaway bet big on the U.S. housing market. You probably shouldn’t follow suit.
Homebuilder stocks are cheap, but it’s not easy to time a rebound in the depressed housing market. Source：MarketWatch
Pressure on bonds abates as Treasury announces buybacks. What may come next.
The Treasury Department said Wednesday that it will more than double the size of governmentdebt buybacks, sending yields sharply lower and stocks higher at the…
I’m leaving my grandkids money — but they must pass financial-literacy classes to get it. Is that fair?
“I do believe very much in delayed gratification.” Source：MarketWatch
Marvell’s stock surges on news of Google chip deal — and Broadcom’s falls
Google will also get the option to purchase about $12 billion worth of Marvell’s stock. Source：MarketWatch
SK Hynix suggests its stock is too cheap as it embarks on $29 billion buyback
Following a sharp selloff in recent months, the South Korean memorychip company says current share prices don’t reflect the business’s “intrinsic value.”…
Moderna’s stock doubles on promising cancer-vaccine results
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda. Source：MarketWatch